<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="sub-section" /><meta name="keywords" content="Alkylating drugs; Cyclophosphamide; Acrolein; Mesna; Ifosfamide; Chlorambucil; Melphalan; Busulfan; Busulphan see Busulfan; Leukaemia: chronic myeloid; Lomustine; Bendamustine; Carmustine; Estramustine; Prostate cancer: estramustine; Treosulfan; Thiotepa; Malignant effusions; Mitobronitol" /><meta name="IX" content="Alkylating drugs; Cyclophosphamide; Acrolein; Mesna; Ifosfamide; Chlorambucil; Melphalan; Busulfan; Leukaemia: chronic myeloid; Lomustine; Bendamustine; Carmustine; Estramustine; Prostate cancer: estramustine; Treosulfan; Thiotepa; Malignant effusions; Mitobronitol" /><meta name="IXN" content="Busulphan see Busulfan" /><title>8.1.1 Alkylating drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="4677.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="4677.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=4677.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2075.htm">8 Malignant disease and immunosuppression</a> &gt; <a href="4676.htm">8.1 Cytotoxic drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4702.htm" title="Previous: MESNA">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="211004.htm" title="Next: BENDAMUSTINE HYDROCHLORIDE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_4677">8.1.1 Alkylating drugs</h1><?highlighter on?><div id="pC" class="jN"><div><p>Extensive experience is available with these drugs, which are among
the most widely used in cancer chemotherapy. They act by damaging
DNA, thus interfering with cell replication. In addition to the side-effects
common to many cytotoxic drugs (<a title="topic: Side-effects of cytotoxic drugs" href="100100.htm#_100100">section 8.1</a>), there are two problems associated
with prolonged usage. Firstly, gametogenesis is often severely affected
(<a title="target-block: Cytotoxic drugs: Reproductive function" href="100100.htm#_100100.2">section 8.1</a>). Secondly, <span id="_4677.7">prolonged
use</span> of these drugs, particularly when
combined with extensive irradiation, is associated with a marked increase
in the incidence of acute non-lymphocytic leukaemia.</p><div id="_1199881355847"><p><b><span>Cyclophosphamide</span></b> is used mainly in combination
with other agents for treating a wide range of malignancies, including
some leukaemias, lymphomas, and solid tumours. It is given by mouth
or intravenously; it is inactive until metabolised by the liver. <span id="_4677.1">A urinary metabolite
of <span>cyclophosphamide</span>, acrolein, can cause haemorrhagic cystitis; this is a rare but serious
complication; increased fluid intake for 24–48 hours after intravenous
injection, can prevent this complication. When high-dose therapy (e.g.
more than 2 g intravenously) is used or when the patient is considered
to be at high risk of cystitis (e.g. because of pelvic irradiation), <span>mesna</span> (given initially intravenously then by mouth)
can also help prevent cystitis—see under Urothelial Toxicity (<a title="BNF:monograph-family: Urothelial toxicity" href="82007.htm#_82007">section 8.1</a>).</span></p></div><div id="_4677.2"><p><b><span>Ifosfamide</span></b> is related to <span>cyclophosphamide</span> and is
given intravenously; <span>mesna</span> (<a title="BNF:monograph-family: Urothelial toxicity" href="82007.htm#_82007">section 8.1</a>) is routinely
given with it to reduce urothelial toxicity.</p></div><div id="_1199881583333"><p><b><span>Chlorambucil</span></b> is used either alone
or in combination therapy for some lymphomas and chronic leukaemias.
It is given by mouth. Side-effects, apart from bone-marrow suppression,
are uncommon. <span id="_4677.3">However, patients occasionally develop severe widespread rashes which
can progress to Stevens-Johnson syndrome or to toxic epidermal necrolysis. If a rash occurs further <span>chlorambucil</span> is contra-indicated and <span>cyclophosphamide</span> is substituted. </span></p></div><div id="_1199881642954"><p><b><span>Melphalan</span></b> is licensed for the treatment of multiple
myeloma, polycythaemia vera, childhood neuroblastoma, advanced ovarian
adenocarcinoma, and advanced breast cancer. However, in practice,
melphalan is rarely used for ovarian adenocarcinoma; it is no longer
used for advanced breast cancer. Melphalan is also licensed for regional
arterial perfusion in localised malignant melanoma of the extremities
and localised soft-tissue sarcoma of the extremities. Interstitial
pneumonitis and life-threatening pulmonary fibrosis are rarely associated
with melphalan.</p></div><div id="_1199881688766"><p><b><span>Busulfan</span> </b>is given by mouth to treat chronic myeloid
leukaemia. Busulfan given by mouth or intravenously, followed by cyclophosphamide,
is also licensed as conditioning treatment before haematopoietic stem-cell
transplantation in adults and children. <span id="_4677.4">Frequent blood tests are necessary
because excessive myelosuppression may result in irreversible bone-marrow
aplasia</span>. Rarely, progressive pulmonary
fibrosis is associated with busulfan. Skin hyperpigmentation is a
common side-effect of oral therapy.</p></div><div id="_1199881732688"><p><b><span>Lomustine</span></b> is a lipid-soluble nitrosourea and is
given by mouth. It is used mainly to treat Hodgkin’s disease resistant
to conventional therapy, malignant melanoma and certain solid tumours. <span id="_4677.5">Bone-marrow toxicity is delayed,
and the drug is therefore given at intervals of 4 to 6 weeks. Permanent bone-marrow damage can occur with prolonged use</span>. Nausea and vomiting are common and moderately severe.</p><p><span id="_213730"><b><span>Bendamustine</span></b> given intravenously is licensed for the treatment of chronic lymphocytic
leukaemia, non-Hodgkin’s lymphoma, and for the treatment of multiple
myeloma.</span> </p><p>The <a title="BNF:target-block: NICE and Scottish Medicines Consortium" href="29404.htm#_200790"><i>Scottish Medicines
Consortium</i></a> has advised (March 2011) that bendamustine (<span class="cZ">Levact</span>®) is accepted for restricted use within NHS Scotland for the treatment
of chronic lymphocytic leukaemia in patients for whom fludarabine
combination chemotherapy is not appropriate.</p><div class="cN"><h2 class="cBR">NICE guidance</h2><h3 class="cBP">Bendamustine for the first-line treatment of chronic
lymphocytic leukaemia (February 2011)</h3><p>Bendamustine is recommended as an option for the treatment of
chronic lymphocytic leukaemia in patients for whom fludarabine combination
chemotherapy is not appropriate.</p></div></div><div id="_1199881766376"><p><b><span>Carmustine</span></b> given intravenously has similar activity
to <span>lomustine</span>; it is given to patients with multiple
myeloma, non-Hodgkin’s lymphomas, and brain tumours. <span id="_4677.6">Cumulative renal damage and delayed
pulmonary fibrosis may occur with intravenous use</span>. Carmustine implants are licensed for intralesional use in adults
for the treatment of recurrent glioblastoma multiforme as an adjunct
to surgery. Carmustine implants are also licensed for high-grade malignant
glioma as adjunctive treatment to surgery and radiotherapy.</p><div class="cN"><h3 class="cBP">NICE guidance (carmustine implants and temozolomide
for the treatment of newly diagnosed high-grade glioma)</h3><p>See  <a title="target-block: Carmustine implants and temozolomide - high grade glioma" href="11772.htm#_200063">Dacarbazine and Temozolomide</a></p></div></div><p><b>Estramustine</b> is a combination of an
oestrogen and chlormethine used predominantly in prostate cancer. It is
given by mouth and has both an antimitotic effect and (by reducing
testosterone concentration) a hormonal effect.</p><div id="_1199881817297"><p><b><span>Treosulfan</span></b> is given by mouth or by intravenous or intraperitoneal
administration and is used to treat ovarian cancer. Skin pigmentation
is a common side-effect and allergic alveolitis, pulmonary fibrosis
and haemorrhagic cystitis occur rarely.</p></div><div id="_1199881861329"><p><b><span>Thiotepa</span></b> is usually used as an intracavitary drug
for the treatment of malignant effusions or bladder cancer (<a title=" Bladder instillations and urological surgery" href="4657.htm#_4657">section 7.4.4</a>). It is
also occasionally used to treat breast cancer, but requires parenteral
administration.</p></div><p><b>Mitobronitol</b> is occasionally used to treat chronic
myeloid leukaemia; it is available on a named-patient basis from <a title="BNF:appendix: Special-order Manufacturers" href="106216.htm#_106216">specialist importing companies</a>.</p></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_211004"><a href="211004.htm" title="BENDAMUSTINE HYDROCHLORIDE">BENDAMUSTINE HYDROCHLORIDE</a></li><li id="_4678"><a href="4678.htm" title="BUSULFAN">BUSULFAN</a></li><li id="_4680"><a href="4680.htm" title="CARMUSTINE">CARMUSTINE</a></li><li id="_4682"><a href="4682.htm" title="CHLORAMBUCIL">CHLORAMBUCIL</a></li><li id="_4684"><a href="4684.htm" title="CYCLOPHOSPHAMIDE">CYCLOPHOSPHAMIDE</a></li><li id="_4687"><a href="4687.htm" title="ESTRAMUSTINE PHOSPHATE">ESTRAMUSTINE PHOSPHATE</a></li><li id="_4689"><a href="4689.htm" title="IFOSFAMIDE">IFOSFAMIDE</a></li><li id="_4691"><a href="4691.htm" title="LOMUSTINE">LOMUSTINE</a></li><li id="_4693"><a href="4693.htm" title="MELPHALAN">MELPHALAN</a></li><li id="_4697"><a href="4697.htm" title="THIOTEPA">THIOTEPA</a></li><li id="_4699"><a href="4699.htm" title="TREOSULFAN">TREOSULFAN</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4702.htm">Previous: MESNA</a> | <a class="top" href="4677.htm#">Top</a> | <a accesskey="]" href="211004.htm">Next: BENDAMUSTINE HYDROCHLORIDE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>